AIM: To describe the clinical characteristics and risk factors of adults <35 years with type 2 diabetes (T2DM). METHODS: Observational study of 185 younger adults attending a specialist diabetes clinic. RESULTS: In this cohort 65% were female, 51% Caucasian, 43% South Asian. Characteristics at presentation: age 24 ± 5.5 years, BMI 33 ± 7.6 kg/m(2) and HbA1c 9.0% ± 2.3. Follow up of 3.2 ± 2.8 years with a diabetes duration of 4.5 ± 3.6 years. HbA1c had improved compared with diagnosis (8.3 ± 2.2% vs. 9.0% ± 2.3%, p<0.0001), but 63% still had an HbA1c>7%. Oral anti-diabetic drugs were used in 72%, insulin alone in 19% and both in 26%. 41% had a BP ≥ 140/80 mmHg, 78% total cholesterol >4 mmol/l, 63% LDL >2 mmol/l, 56% triglycerides >1.7 mmol/l. From diagnosis only the cholesterol and LDL improved significantly, with a modest increase in primary prevention therapy (statin 12-26%, p<0.0001, anti-hypertensives 16-29%, p<0.0001, aspirin 8-12%, p=0.18). 13% had retinopathy, 21% microalbuminuria. 46% had not been reviewed within the past year. CONCLUSIONS: This group represents an extreme phenotype with a high prevalence of insufficiently treated metabolic risk factors. There is need for tailored management strategies to engage and aggressively manage this high-risk group.
AIM: To describe the clinical characteristics and risk factors of adults <35 years with type 2 diabetes (T2DM). METHODS: Observational study of 185 younger adults attending a specialist diabetes clinic. RESULTS: In this cohort 65% were female, 51% Caucasian, 43% South Asian. Characteristics at presentation: age 24 ± 5.5 years, BMI 33 ± 7.6 kg/m(2) and HbA1c 9.0% ± 2.3. Follow up of 3.2 ± 2.8 years with a diabetes duration of 4.5 ± 3.6 years. HbA1c had improved compared with diagnosis (8.3 ± 2.2% vs. 9.0% ± 2.3%, p<0.0001), but 63% still had an HbA1c>7%. Oral anti-diabetic drugs were used in 72%, insulin alone in 19% and both in 26%. 41% had a BP ≥ 140/80 mmHg, 78% total cholesterol >4 mmol/l, 63% LDL >2 mmol/l, 56% triglycerides >1.7 mmol/l. From diagnosis only the cholesterol and LDL improved significantly, with a modest increase in primary prevention therapy (statin 12-26%, p<0.0001, anti-hypertensives 16-29%, p<0.0001, aspirin 8-12%, p=0.18). 13% had retinopathy, 21% microalbuminuria. 46% had not been reviewed within the past year. CONCLUSIONS: This group represents an extreme phenotype with a high prevalence of insufficiently treated metabolic risk factors. There is need for tailored management strategies to engage and aggressively manage this high-risk group.
Authors: Sophia Y Wang; Chris A Andrews; William H Herman; Thomas W Gardner; Joshua D Stein Journal: Ophthalmology Date: 2016-11-30 Impact factor: 12.079
Authors: Jun Jie Benjamin Seng; Amelia Yuting Monteiro; Yu Heng Kwan; Sueziani Binte Zainudin; Chuen Seng Tan; Julian Thumboo; Lian Leng Low Journal: BMC Med Res Methodol Date: 2021-03-11 Impact factor: 4.615
Authors: Anjali Gopalan; Maruta A Blatchins; Andrea Altschuler; Pranita Mishra; Issa Fakhouri; Richard W Grant Journal: J Gen Intern Med Date: 2021-01-26 Impact factor: 5.128